Fintel reports that on December 17, 2025, Barclays upgraded their outlook for Summit Therapeutics (NasdaqGM:SMMT) from Underweight to Equal-Weight.
Analyst Price Forecast Suggests 93.60% Upside
As of December 6, 2025, the average one-year price target for Summit Therapeutics is $32.93/share. The forecasts range from a low of $12.12 to a high of $44.10. The average price target represents an increase of 93.60% from its latest reported closing price of $17.01 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Summit Therapeutics is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -0.30.
What is the Fund Sentiment?
There are 464 funds or institutions reporting positions in Summit Therapeutics. This is an increase of 13 owner(s) or 2.88% in the last quarter. Average portfolio weight of all funds dedicated to SMMT is 0.14%, an increase of 12.89%. Total shares owned by institutions increased in the last three months by 4.79% to 109,279K shares. 
The put/call ratio of SMMT is 1.04, indicating a bearish outlook.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 33,723K shares representing 4.37% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 4,539K shares representing 0.59% ownership of the company. In its prior filing, the firm reported owning 3,905K shares , representing an increase of 13.96%. The firm increased its portfolio allocation in SMMT by 6.57% over the last quarter.
Geode Capital Management holds 3,133K shares representing 0.41% ownership of the company. In its prior filing, the firm reported owning 2,935K shares , representing an increase of 6.32%. The firm decreased its portfolio allocation in SMMT by 49.90% over the last quarter.
PRHSX - T. Rowe Price Health Sciences Fund holds 2,747K shares representing 0.36% ownership of the company.
XBI - SPDR(R) S&P(R) Biotech ETF holds 2,432K shares representing 0.32% ownership of the company. In its prior filing, the firm reported owning 2,814K shares , representing a decrease of 15.73%. The firm increased its portfolio allocation in SMMT by 0.95% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
